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ABSTRACT
CD34-selection of hematopoietic grafts for patients undergoing autologous hematopoietic stem cell trans-
plantation (HSCT) is frequently used to obtain a tumor-free graft. The majority of published experience is with
peripheral blood stem cell (PBSC) products; only scant information has been published on bone marrow (BM)
grafts. We reviewed our experience using CD34 selection of BM grafts in children undergoing autologous
BM transplantation. After obtaining institutional approval, we performed a retrospective review of the medical
records of patients who underwent autologous stem cell collection at St. Jude. From January 1, 1999, to
December 31, 2003, 373 patients underwent autologous HSCT; 131 received marrow grafts, 237 received
PBSC grafts, and 5 received a combination. Seventeen patients underwent BM harvests for CD34 selection
of their stem cell grafts. Sixteen patients received 19 CD34 purified grafts processed on the Isolex 300i
Magnetic Cell Selection System® device. Four patients were not included in the engraftment analysis as 1 did
not receive the collected product, 1 received a tandem product, and 2 received products that were composed
of 2 or 3 combined purified products. Following selection, marrow grafts contained a median of 1.4  106
CD34 cells/kg (range: 0.09-8.3  106/kg) and a median of 0.014 108 total nucleated cell cells/kg (range:
0.001-0.09  108/kg). The median CD34% recovery was 30.9% (range: 9.3%-57.1%), with the median CD34
purity being 95.5% (range: 62.2%-98.8%). All patients engrafted. The median time to absolute neutrophil
count >500/mm3 was 19 days (range: 12-35 days), and to platelet recovery was 28 days (range 18-37 days). No
patient died from transplant-related complications. Our study demonstrates that CD34-selection of marrow
grafts is feasible, and these grafts are able to successfully reconstitute hematopoiesis in patients undergoing
autologous BMT.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
CD34 positive (CD34) selection of hematopoi-
tic progenitor cells has been used to obtain highly
uriﬁed tumor-free grafts in patients with malignan-
ies who require autologous hematopoietic stem cell
ransplantation (HSCT) [1-3]. CD34 selection
erves as a measure of tumor purging, provided the
umor cells do not express the CD34 antigen [4, 5]. s
08he only commercially available methodology in the
nited States to perform this procedure is the Isolex
00i Magnetic Cell Selection System® device (Baxter,
eerﬁeld, IL) (Isolex®) [6]. This device uses a murine
ntibody to the human CD34 antigen to select hema-
opoietic cells expressing the CD34 antigen. The spe-
iﬁc licensed use of the Isolex® device is for CD34election of hematopoietic stem cells from autologous
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CD34 Selection for Pediatric Autologous HSCT 609eripheral blood of patients with malignancies. The
ajority of published literature has described its use in
rocessing peripheral blood stem cell (PBSC) grafts of
atients with breast cancer, multiple myeloma, and
ymphoma [2,7-10]. CD34-selected grafts have re-
roducibly resulted in acceptable neutrophil and
latelet engraftment in these circumstances [1]. In
ediatrics, this methodology is used to purify PBSC
rafts of patients undergoing autologous HSCT for
alignancies with a tendency to metastasize to the
arrow, such as neuroblastoma, lymphoma, and other
olid tumors [5, 11, 12]. Unfortunately, many patients
re unable to have sufﬁcient numbers of peripheral
lood stem cells collected for HSCT, whereas other
atients may be too small to undergo apheresis. In
hese situations, a bone marrow (BM) harvest is indi-
ated. However, BM grafts are reported to have a
igher frequency of tumor contamination than pe-
ipheral blood grafts [10]. In addition, unmanipulated
arrow grafts are composed of larger volumes and
hus have larger dimethylsulfoxide (DMSO) content
han PBSC grafts. The DMSO present in the graft
an cause cardiovascular adverse events such as hyper-
ension and bradycardia. Although CD34 selection
ay decrease the graft tumor content, it will decrease
raft volume, allowing for smaller amounts of DMSO
or cryopreservation, and hopefully fewer adverse
vents. At our institution, we have used the Isolex®
evice to purify both peripheral blood and BM grafts
or pediatric and adolescent patients undergoing au-
ologous HSCT. In this article, we describe our insti-
utional experience using CD34 selection of marrow
rafts from patients undergoing autologous BM trans-
lant (BMT). To our knowledge, this is the ﬁrst pub-
ished series describing CD34 selection involving
utologous BM grafts.
ATERIALS AND METHODS
atients
We performed a retrospective, St. Jude institu-
ional review board-approved study on BM grafts that
ere processed on the Isolex® device. Between Janu-
ry 1, 1999, and December 31, 2003, 373 autologous
SCT procedures were performed at St. Jude Chil-
ren’s Research Hospital. Categorically, 237 received
nly PBSC grafts, 131 received only marrow grafts,
nd 5 received both peripheral blood and marrow
rafts. Of the patients receiving the 131 marrow
rafts, diagnoses included brain tumors (n 
1 grafts), neuroblastoma (n  31 grafts), Hodgkin
ymphoma (n  5 grafts), sarcoma (n  4 grafts),
on-Hodgkin’s lymphoma (NHL) (n  3 grafts),
ilm’s tumor (n  2 grafts), germ cell tumor (n  2
rafts), severe combined immunodeﬁciency (n  2
rafts), and hepatoblastoma (n  1 graft). Seventeen Satients had marrow grafts processed on the Isolex®
evice, comprising 20 marrow products. Thirteen pa-
ients received this product as the sole graft. All 20
roducts were included in the processing analysis.
our patients were excluded from the engraftment
nd survival data: (a) 1 patient did not receive his
utologous product and later underwent an allogeneic
SCT, (b) 1 received a tandem transplant, (c) 1 re-
eived a combination of 2 selected grafts, and (d) 1
eceived a combination graft composed of 1 PBSC and
BM products, all selected. No patient received
rowth factors immediately prior to the marrow har-
est; all patients had steady-state BM grafts collected.
hese patients underwent a BM harvest because they
eighed 10 kg (n  2) or had failed PBSC mobili-
ation (n  15). We compared these patients to 7
atients who received a single, unmanipulated, auto-
ogous BM infusion and had a similar diagnosis as those
ho received a single, Isolex® device processed autolo-
ous BM graft. Those who received tandem transplants,
hose who received a non-Isolex® device manipulated
raft, or who had a diagnosis other than neuroblastoma
r NHL were excluded from the data analysis.
raft Procurement
Patients underwent harvest when the marrow was
orphologically free of tumor. After a physician ob-
ained informed consent from the legal guardian, the
atient underwent the BM harvest in the operating
oom under sterile conditions with general anesthesia.
he goal was to collect a BM graft that contained
1  108 total nucleated cell (TNC)/kg with a maxi-
um collection volume of 20% total blood volume or
5 mL/kg, whichever was greater. If insufﬁcient cells
ere collected with 1 harvest, subsequent ones were
erformed prior to the initiation of the transplant
onditioning regimen. The decision to collect more
arrow stem cells was made by the patient’s trans-
lant physician and the laboratory medical director
fter completion of the processing procedure and the
nalysis of the CD34 enriched product.
raft Processing
The manufacturer provided guidelines for CD34
election using the Isolex® device (Version 2.5). Ac-
ording to manufacturer’s instructions, the starting
aterial, the peripheral blood progenitor cell/mono-
uclear cell product, was to contain 8.0  1010
ucleated cells and 35 mL of red blood cells. In our
tudy, the same limits were applied to the processing
f BM cells on the Isolex® device. Grafts were pro-
essed on the day of collection.
M Preparation
Bone marrow products were processed within the
tem Cell Processing section of the Human Applica-
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K. A. Kasow et al.610ions Laboratory according to standard operating pro-
edures of the laboratory. Each product was initially
ssessed for volume, cell count, mononuclear cell con-
ent, hematocrit, and CD34 content. To minimize the
mount of cell loss prior to CD34 selection, an in-
erted centrifugation procedure (400 g for 10 min-
tes) rather than density gradient separation was per-
ormed. Red blood cells were carefully withdrawn
rom the products to target a ﬁnal red blood cell content
f 35 mL. Following red blood cell removal, ﬁnal
BC content resulted in a mean volume of 21.5 mL
range: 12.0-28.1 mL). The maximum loading volume
or the Isolex® device is 1000 mL, with a maximum
roduct hematocrit being 5.0%. Each product was
iluted with Isolex Working Buffer (Dulbecco’s phos-
hate-buffered saline supplemented with 1.0% human
erum albumin and 0.48% sodium citrate [w/v]).
D34 Selection
The Isolex 300i Magnetic Cell Selection System®
s an automated system employing a microprocessor-
ontrolled instrument, dedicated reagents, and dispos-
ble tubing set. The cells are sensitized with a mouse
ntihuman monoclonal antibody directed against the
D34 antigen. The CD34 cell-antibody complexes
re then incubated with immunomagnetic beads
Dynabeads® M-450 Sheep anti-Mouse IgG, Dynal
iotech, ASA, California), which are coated with
heep antimouse antibody (Ab), resulting in bead-Ab-
D34 cell complexes. The complexes are isolated
sing the primary magnet of the Isolex® device.
hrough a releasing agent, a peptide resembling
D34 antigen, the CD34 cells are released from the
ead, washed, and collected in the ﬁnal processing
tep on the Isolex® device while the beads remain
ttached to the magnet.
D34 Positive Fraction
Each CD34 product was concentrated by cen-
rifugation to remove the Isolex Working Buffer and
esuspended with Plasma-Lyte 148 and 5% Dextrose
ith 5% human serum albumin according to standard
perating procedures of the Human Applications Lab-
ratory. The ﬁnal product was assessed for cell count,
iability, CD34 content, and sterility. All products
ere cryopreserved with 10% DMSO in a control rate
reezer and stored in liquid nitrogen until being
hawed for infusion.
raft Tumor Analysis
If possible, an aliquot of the graft was obtained
rior to and following CD34 selection for tumor as-
essment. Samples from neuroblastoma patients were
nalyzed for the presence of tyrosine hydroxylase,
ynaptophysin, and dopamine decarboxylase by re-
erse transcriptase polymerase chain reaction sRT-PCR). The sensitivity of the assay was 1:100,000
ells for tyrosine hydroxylase and dopamine decarbox-
lase, and 1:1,000 cells for synaptophysin.
ransplant Care and Patient Management
All patients were transplanted on St. Jude institu-
ional review board-approved protocols, and this ret-
ospective study was also approved by the St. Jude
nstitutional review board. The patient with NHL
eceived total body irradiation (TBI) 12 Gy and eto-
ophos 60 mg/kg. Patients with neuroblastoma re-
eived 1 of 2 regimens: (a) cyclophosphamide 375
g/m2 with targeted dosing of topotecan [13], or (b)
elphalan 140 mg/m2 with 16 targeted doses of
usulfan [14]. Cryopreserved stem cell products were
nfused by intravenous push through a central venous
atheter at a minimum of 24 hours after the last dose
or chemotherapy. Patients received irradiated, sin-
le donor, leukocyte-reduced blood products.
acked red blood cells were transfused in a volume of
0 cc/kg to maintain hemoglobin 8 g/dL and plate-
et apheresis products were transfused to maintain
latelets 20,000/mm3. All patients received granu-
ocyte-colony stimulating factors (G-CSF) 5 g/kg/
ay after stem cell infusion until absolute neutrophil
ount (ANC) 2000/mm3 for 2 consecutive days.
eutrophil engraftment was deﬁned as ANC 500/
m3 for 3 consecutive days. Platelet engraftment was
eﬁned as platelet count 20,000/mm3 and 50,000/
m3 for 7 consecutive days without transfusion sup-
ort, respectively. Time to lymphocyte recovery (ab-
olute lymphocyte count500/mm3) from the time of
SCT was also collected. All patients received pro-
hylaxis for Pneumocystis carinii pneumonia; antifungal
nd antiviral prophylaxes were not routinely adminis-
ered. Adverse events were coded according to Na-
ional Cancer Institute Common Toxicity Criteria,
ersion 2.0 [15].
ESULTS
atient Characteristics
The 17 patients in this study who had marrow
rafts collected were a median age of 4 years (range:
-18 years) at the time of collection. Seven patients
ere males, and diagnoses included neuroblastoma
n  15), and NHL (n  2). One NHL patient had
xtensive bone metastasis, including the pelvic region,
nd the second NHL patient had previous morpho-
ogic BM involvement. Thus, to reduce the concern of
umor contamination, products from these 2 patients
ere processed on the Isolex® device.
During this same time period, 5 patients with
euroblastoma and 2 with NHL received unmanipu-
ated, autologous BM grafts as a single product after a
ingle collection.
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CD34 Selection for Pediatric Autologous HSCT 611raft Characteristics
Characteristics of the 20 grafts prior to CD34
election are described in Table 1. Prior to selection,
he BM grafts contained a median of 5.8  106
D34/kg (range: 0.4-25.5  106/kg) and 2.9  108
NC/kg (range: 0.4-5.6  108/kg). The median
D34% prior to selection was 2.48% (range: 0.58%-
.67%). The median diluted product volume was 632
L (range: 500-901 mL), and the median preselection
ematocrit was 3.0% (range: 1.6%-4.0%).
Following CD34 selection, marrow grafts con-
ained a median of 1.4  106 CD34 cells/kg (range:
.09-8.3  106/kg) and a median of 0.01  108 TNC
ells/kg (range: 0.001-0.09  108/kg). The median
raft purity was 95.5% (range: 62.2%-98.9%), with 16
rafts having a CD34 purity 90%. The median
D34% recovery was 30.9% (range: 9.3%-57.1%).
he median volume of each cryopreserved BM infu-
ion was 34 mL (range: 9.2-37.6 mL) (Table 2). The
atient who underwent a tandem procedure required
nly 1 BM harvest to obtain a sufﬁcient number of
D34 hematopoietic stem cells. One patient re-
uired 3 (product numbers 4, 6, and 7) and another
equired 2 (product numbers 3 and 5) harvests to
btain a sufﬁcient number of progenitor cells to pro-
able 1. Graft Characteristics of the 20 Bone Marrow Collections Obta
reselection Collection Volumes, and Hematocrit
Product ID#: Recipient Weight (kg)
Starting Dose V
TNC 108 CD
1 12.1 3.76
2 10.7 2.03
3 19.6 1.77
4 85.2 1.5
5 19.7 2.94
6 87.3 2.95
7 90.1 0.41
8 10.8 2.82
9 24.6 2.91
10 19.8 4.11
11 86.7 5.07
12 18.3 2.6
13 15.1 0.83
14 14.7 2.43
15 10.7 4.95
16 13.2 3.68
17 15.9 5.62
18 10.8 4.5
19 12.2 4.4
20 18.6 1.79
Mean 29.8 3.05
Median 17.1 2.93
St. Dev. 29.8 1.44
Range
Low 10.7 0.41
High 90.1 5.62
nformation regarding the mean, median, standard deviation, and r
NC indicates total nucleated cell count; HCT, hematocrit.eed to autologous HSCT. All patients had appropri- rte doses of stem cells cryopreserved prior to the
nitiation of the conditioning regimen. For the 13
atients who received a single product, the median
D34 cell count of these infused grafts was 2.5 
06 cells/kg (range: 05-8.3  106 cells/kg). In com-
arison, those who received unmanipulated BM grafts
ad a median CD34 cell count of 2.6  106 cells/kg
range: 0.7-10.4  106 cells/kg).
raft Tumor Content
After collection and prior to processing, 7 samples
ere not tested for residual tumor content, 3 were
nsufﬁcient for analysis, and 10 were tested and found
o have no detectable disease. After processing, 8
amples were not evaluated for residual tumor, and
he 12 samples tested did not have detectable dis-
ase. Four products were collected from the 2 pa-
ients with NHL. For the remaining 16 products
rom neuroblastoma patients, 4 had insufﬁcient cell
ount to evaluate the product for residual tumor.
his data was not used to predict relapse rate, as it
ad to be interpreted with extreme caution as nor-
al cells also express tyrosine hydroxylase, synap-
ophysin, and dopamine decarboxylase (S. Shurtleff,
ersonal communication). This method did not cor-
ior to Processing, Including TNC and CD34 Cell Dose/kg, CD34%,
kg
Starting % CD34 Pre-Isolex Diluted Vol. Pre-Isolex HCT06
4.22 500.62 4.0
3.49 500.00 3.9
2.95 505.00 3.7
2.97 760.00 3.7
2.79 550.00 3.4
1.78 640.00 3.9
0.96 699.80 3.8
4.18 600.00 2.0
4.72 699.50 2.9
0.93 700.00 3.9
0.58 837.00 2.4
1.37 700.00 3.2
2.11 901.00 1.6
2.17 605.00 2.8
1.64 500.00 2.8
2.12 624.00 2.6
0.98 904.40 3.0
5.67 604.30 2.5
4.06 618.20 2.5
3.39 750.50 2.5
2.65 659.97 3.0
2.48 632.00 3.0
1.43 125.57 0.7
0.58 500.00 1.6
5.67 901.00 4.0
is also provided for each column.ined Pr
alues/
34 1
15.87
7.08
5.21
4.44
7.03
5.07
0.39
11.79
13.74
3.82
2.89
3.56
1.76
5.27
8.12
7.8
5.51
25.52
17.86
6.06
7.94
5.79
6.16
0.39
25.52
angeselate with risk of relapse. Of the 12 neuroblastoma
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K. A. Kasow et al.612atients, 7 (58.3%) have experienced disease re-
apse. Of the 4 neuroblastoma products not tested, 2
f the 3 patients are currently alive and the third
atient died of disease.
linical Outcome
Sixteen patients received processed products and
one experienced adverse reactions during the stem
ell infusion. All 13 patients who received nontandem,
ingle selected BM products engrafted. No adverse
eactions to the cryopreservative, DMSO occurred.
he median time to neutrophil engraftment was 19
ays (range: 12-35 days). The median time to lym-
hocyte recovery was 31 days (range: 16-346 days)
rom HSCT. The median times to platelet count of
0,000/mm3 and 50,000/mm3 were 28 days (range:
8-37 days) and 29 days (range: 20-44 days), respec-
ively. The median times to last red blood cell and
latelet transfusion were 25 days (range: 15-182 days)
nd 21 days (range: 11-279 days) after HSCT, respec-
ively. Five patients experienced infectious complica-
ions; 2 with Staphylococcus species bacteremia (days1
nd 79) and 3 with diagnostic imaging consistent
ith pneumonia, 1 presumed to be Candida (days 9,
able 2. Graft Characteristics of the 20 Bone Marrow Collections after
inal CD34%, the Percentage of CD34 Cells Recovered from the Proces
Product ID#:
Final Dose Values/kg
TNC 108 CD34 106
1 0.041 4.03
2 0.012 0.76
3 0.011 1.10
4 0.006 0.63
5 0.014 1.39
6 0.006 0.46
7 0.001 0.09
8 0.054 4.97
9 0.026 2.47
10 0.014 1.28
11 0.006 0.59
12 0.014 1.35
13 0.007 0.51
14 0.017 1.59
15 0.039 3.82
16 0.025 2.36
17 0.028 2.51
18 0.090 8.30
19 0.047 4.66
20 0.010 1.17
Mean 0.023 2.20
Median 0.014 1.37
St. Dev. 0.022 2.04
Range
Low 0.001 0.09
High 0.090 8.30
ne patient who had undergone collection did not receive the CD
deviation, and ranges is also provided for each column.
NC indicates total nucleated cell count.11, and39). No patient died from regimen-related foxicity, infection, or hemorrhage. Ten patients had
isease recurrence at a median of 324 days (range:
69-528 days) following HSCT. One of these patients
emains alive3.5 years after HSCT, and 9 have died,
ll of recurrent disease. Six patients are alive disease
ree, at a median of 1291 days (range: 1127-1570 days)
fter autologous HSCT.
In comparison, 7 patients (5 neuroblastoma and 2
HL) received nonselected BM grafts during this
ime period. One patient experienced hypertension
nd sinus bradycardia secondary to the DMSO. The
edian time to neutrophil engraftment was 18 days
range: 10-44), and the median time for lymphocyte
ecovery for 6 patients was 37 days (range: 17-56
ays). Five patients had a platelet count of 20,000/
m3 at a median of 25 days (range: 17-91 days), and 4
atients had a platelet count of 50,000/mm3 at a me-
ian of 23 days after HSCT. Two patients did not
ave platelet engraftment by day 100 after HSCT, and
nother did not have a platelet count of 50,000/mm3
y this time point. Two patients had infectious com-
lications after the initiation of conditioning: adeno-
irus in stool (1 patient, day 3) and oral herpes
implex virus (1 patient, day 6). No patient died
Selection, Including the Final TNC and CD34 Cell Dose/kg, the
d the Volume Infused
al % CD 34 % CD34 Recovery Volume Infused (mL)
98.08 29.8 17.0
62.24 11.8 9.2
98.42 21.1 18.2
96.88 14.1 20.0
96.71 21.3 19.5
83.44 9.3 19.8
91.1 23.1 10.0
92.05 42.9 37.0
94.81 18.6 36.0
91.49 35.6 36.0
97.74 38.3 Not infused
96.18 40.4 34.0
72.68 29.0 34.0
93.34 31.9 32.0
97.92 57.1 36.0
94.27 32.2 35.0
88.86 46.1 36.0
97.83 39.0 37.6
98.79 33.3 36.0
97.63 23.8 37.0
92.023 29.93 28.44
95.495 30.86 34.00
9.40156 12.26 10.02
62.24 9.30 9.2
98.88 57.10 37.6
ected product. Information regarding the mean, median, standardCD34
sing, an
Fin
34 selrom regimen-related toxicity, infection, or hemor-
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CD34 Selection for Pediatric Autologous HSCT 613hage. Currently 6 patients are alive after autologous
SCT and 1 died of progressive disease.
ISCUSSION
This study demonstrates that CD34 selection of
M grafts on the Isolex 300i Magnetic Cell Selection
ystem® is feasible for pediatric and adolescent pa-
ients. No detectable tumor content and prompt neu-
rophil and platelet engraftment can be achieved with
his processed graft. Although great cell loss during
rocessing occurs, engraftment is not compromised,
s all of our study patients recovered neutrophil and
latelet counts in a timely manner. Furthermore, no
dverse effects occurred secondary to the DMSO, and
ew patients had documented infections, all occurring
rior to day 100 after BMT and resolving with appro-
riate therapy.
Several other immunoselection devices besides
he Isolex® device have been used for the puriﬁca-
ion of CD34 stem cells from BM and peripheral
lood, including Ceprate™ (Cellpro, Inc., Bothell,
A) and the CliniMACS® (Miltenyi Biotech, Ber-
isch Gladback, Germany) [6, 16, 17]. Although the
eprate™ is no longer commercially available, these
ystems have been compared to each other. Although
he CliniMACS® tends to achieve a purer CD34
roduct, 1 study demonstrated that the Isolex® pro-
essed product had a greater functional capacity in
ulture [17]. However, all 3 systems did demonstrate
hat neutrophil and platelet engraftment could be ob-
ained after infusing a CD34-enriched graft [16].
Time to engraftment with CD34 selected marrow
rafts was slower than observed with unmanipulated
BSC grafts [18, 19], yet, they were similar to the
imes reported for unmanipulated marrow grafts [19].
lthough neutrophil engraftment was similar to his-
oric controls for disease and time period, platelet
ngraftment was likely slower in our patients because
M was harvested once the marrow was morpholog-
cally free of tumor. Thus, some patients received
dditional courses of chemotherapy prior to marrow
ollection, which resulted in cumulative marrow dam-
ge, leading to a damaged stem cell pool, a well-
escribed phenomenon. Furthermore, we observed no
atal infectious or hemorrhagic complications.
A single BM harvest was sufﬁcient for all but 2
atients to obtain adequate hematopoietic progenitor
ells for transplantation. There was a wide range of
ecoveries of CD34 cells from the selection, which
ay result, in part, from the small numbers of heavily
retreated patients in our series. On average, the me-
ian recovery was 30.9% (range: 9.3%-57.1%) (Table
). This ﬁgure is substantially less than reported from
D34 selections of PBSC products processed on the
solex® device (58.4  19.2%) [6]. Review of the citerature reveals that the CD34 cell recovery from
obilized peripheral blood stem cells processed on
he Isolex® device is quite variable [20-23]. One po-
ential reason for the wide range of CD34 yield is the
tarting red blood cell volume and hematocrit. Those
tarting products that have a lower red cell volume
end to have a higher CD34 yield [21, 23]. Loading
oo many CD34 cells onto the processing machine
ithout enough antibody or magnetic beads may also
e a limiting factor and decrease the yield of the
roduct [21]. Furthermore, in preliminary studies in
ur cell-processing laboratory, we observed that the
eptide releasing agent was not optimized to release
he beads from CD34 cells in BM grafts compared to
BSC grafts. This was an unexpected observation, and
onﬁrmed upon communications with the manufac-
urer. We investigated this issue and conﬁrmed the
resence of many CD34 cells attached to the beads
fter the completion of the processing. An enzymatic-
ased releasing procedure had been used prior to the
urrent use of the peptide releasing agent; the beads
ere released from these residual cells with the en-
yme treatment (P. Eldridge, personal communica-
ion). Although the cell loss did not prevent the avail-
bility of an adequate stem cell graft for most patients,
his may be a potential concern, as some patients may
equire multiple harvests or an additional PBSC col-
ection.
The grafts infused in our series had no evidence of
umor contamination after processing. We cannot
olely attribute this ﬁnding to the graft processing.
atient selection and the timing of the marrow harvest
ay have played a role as we required a morpholog-
cally negative marrow. Potentially, one could hypoth-
size that purging may not have been necessary as the
arrow was already tumor free. However, gene-mark-
ng studies have demonstrated that marrow harvested
rom neuroblastoma patients in morphologic remis-
ion does contribute to disease recurrence after auto-
ogous HSCT [24]. In addition, our assay may not
ave been sensitive enough to identify extremely small
mounts of tumor. Moreover, of the 12 patients tested
or minimal residual disease after selection, 7 patients
ave relapsed versus the 1 in the nonselected group.
hus, we do not have any evidence that this selection
ethod acts as an additional purging process to help
revent relapse disease.
As multiple collections were required for 2 pa-
ients because of low cell dose yield, it may be
mportant in the future to harvest marrow earlier
rrespective of tumor content if CD34-selection is
erformed, with close analysis of the processed graft
or tumor contamination. Collecting and processing
ells earlier in the patient’s treatment course may
esult in an improved hematopoietic cell content and
igher cell dose, providing close analysis of the pro-
essed graft for tumor contamination is undertaken.
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K. A. Kasow et al.614Finally, alternative methodologies, such as the
liniMACS® device, which have lower rates of cell
oss, should be explored. Novel hematopoietic pro-
enitor cell markers such as CD133, which has a more
estricted tissue expression than CD34, should also be
valuated for their role in tumor purging within the
ontext of a clinical trial.
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